Combinatorial Drug Therapy for Treating Resistant Glioblastoma Multiforme

Glioblastoma multiforme (GBM) remains one of the most common and aggressive brain tumors with a high mortality rate despite extensive efforts towards developing new therapeutics. The 5-year survival rate of GBM patients range from 20% – 5%, declining significantly with the patient’s age. Current major cancer treatment modalities, such as radiotherapy and/or chemotherapy, remain incapable to fully eradicate these cancer cells. In addition, while recent clinical studies provide hope with combinatorial treatment using radiation and immunotherapy (radioimmunotherapy) to target GBM, radiation treated GBM tumors eventually gain resistance and begin to evade continued radioimmunotherapy. Thus, there are current unmet needs to develop new treatment regimens for the treatment of radio-resistant GBM.

Researchers at the University of California, Davis, have discovered a potentially new therapeutic target to eliminate radio-resistant tumor cells in GBM with a combinatorial drug treatment. Radio-resistant GBM were found to overexpress CD47 and increase mitochondrial fatty acid oxidation (FAO). Thus, the use of anti-CD47 antibody in combination with FAO inhibitors or blockage of the FAO pathway with genetic manipulations can sensitize these radio-resistant tumor cells as well as prevent their growth and evasion of phagocytosis by the macrophages.

Researchers at the University of California, Davis have discovered a new treatment target to attack and kill GBM cancer cells that evades macrophage phagocytosis and are resistant to radioimmunotherapy.


Contact Information

Name: Raj Gururajan


Phone: 530-754-7637